Samsung Bioepis Presents Long-Term Safety Data of EPYSQLI™ (Eculizumab) in PNH at the European Hematology Association (EHA) Congress 2025

Contributed by: Business Wire

Tags

Health
Clinical Trials
Research
Science
Pharmaceutical
Cardiology
Biotechnology
Samsung Bioepis Co., Ltd.

More Like This

Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Business Wire logo

Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe

Sobi to present new clinical and real-world data at EHA 2026 in Stockholm

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease